Evolyutsiya ad\"yuvantnoy lekarstvennoyterapii «rannego» raka molochnoyzhelezy (mnogotsentrovoeissledovanie)

Authors: Kolyadina IV¹, Poddubnaya IV¹, Frank GA¹, Komov DV¹, Karseladze AI¹, Ermilova VD¹, Vishnevskaya Y.V¹, Makarenko NP¹, Teterin KA¹, Banov SM¹, Guzieva Z.M¹
Affiliations:
Issue: Vol 14, No 1 (2012)
Pages: 16-20
Section: Articles
Submitted: 09.04.2020
Published: 15.03.2012
URL: https://modernonco.orscience.ru/1815-1434/article/view/29466
ID: 29466

Cite item

Full Text

Katalinic A, Bartel C, Raspe H. Beyond mammography screening: quality assurance in breast cancer diagnosis (The Qua Ma Di Project). Br J Cancer 2007; 96 (1): 157-61.
Qin YY, Li H, Guo XJ et al. Adjuvant chemotherapy, with or without taxanes, in early or operable breast cancer: a meta-analysis of 19 randomized trials with 30 698 patients. PLoS One 2011; 6 (11): e26 946.
Wang J, Shi M, Ling R et al. Adjuvant chemotherapy and radiotherapy in triple-negative breast carcinoma: a prospective randomized controlled multi-center trial. Radiother Oncol 2011; 100 (2): 200-4.
Sanpaolo P, Barbieri V, Genovesi D. Prognostic value of breast cancer subtypes on breast cancer specific survival, distant metastases and local relapse rates in conservatively managed early stage breast cancer: a retrospective clinical study. Eur J Surg Oncol 2011; 37 (10): 876-82.
Decker T, Hungermann D, Böcker W. Prognostic and predictive factors of invasive breast cancer: update 2009. Pathologe 2009; 30 (1): 49-55.
Iturbe J, Zwenger A, Leone JP et al. Treatment of early breast cancer, a long-term follow-up study: the GOCS experience. Breast J 2011; 17 (6): 630-7.
Schmidt M. Node-negative breast cancer: which patients should be treated? Breast Care (Basel) 2008; 3 (4): 237-43.

Supplementary Files

Action

1. JATS XML